# China NMPA Drug Inspection - Guilin Nanfang Pharmaceutical Co., Ltd. - Moxifloxacin Hydrochloride Tablets

Source: https://www.keypedia.com/records/china_drug_inspection/guilin-nanfang-pharmaceutical-co-ltd/15605521-617c-49f1-9a35-e03282301781
Source feed: China

> China NMPA drug inspection for Guilin Nanfang Pharmaceutical Co., Ltd. published November 12, 2026. Drug: Moxifloxacin Hydrochloride Tablets. On November 12, 2026, China's National Medical Products Administration (NMPA) issued Announcement No. 39, identifying 27

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 39 of 2026 from the National Medical Products Administration regarding 27 batches of drugs that do not meet the standards.
- Company Name: Guilin Nanfang Pharmaceutical Co., Ltd.
- Publication Date: 2026-11-12
- Drug Name: Moxifloxacin Hydrochloride Tablets
- Inspection Finding: Dissolution
- Action Taken: Risk control measures such as suspending sales and use, and recalling products will be implemented. An investigation will be launched into the reasons for non-compliance, and thorough rectification will be carried out. The provincial drug regulatory authority will initiate an investigation.
- Summary: On November 12, 2026, China's National Medical Products Administration (NMPA) issued Announcement No. 39, identifying 27 batches of non-compliant drugs produced by 17 different companies. Key manufacturers cited in the report include Beijing Tongrentang, Guilin Nanfang Pharmaceutical, Wuhan Hualong Biopharmaceutical, and several specialized firms such as Tibet Shenhou Pharmaceutical and Zhengzhou Zhuofeng Pharmaceutical. The findings resulted from inspections conducted by various regional drug control institutes across China. The reported violations involve significant quality control failures. Specifically, injectable and ophthalmic products were found to contain pyrogens and visible foreign matter, which pose safety risks. Other issues included poor dissolution rates in tablets, improper moisture levels, weight variations, and substandard purity markers like ash content and extractives in traditional Chinese medicine preparations. These failures indicate inconsistencies in manufacturing processes and quality assurance. Under the regulatory framework of the Drug Administration Law of the People's Republic of China, the NMPA has ordered immediate actions. Affected companies must suspend the sale and use of these products and initiate comprehensive recalls. Furthermore, the companies are required to investigate the root causes of these quality deviations and implement corrective measures to prevent recurrence. Provincial authorities are also directed to pursue investigations into potential illegal activities associated with these batches and publicly disclose their findings.

Company: https://www.keypedia.com/companies/guilin-nanfang-pharmaceutical-co-ltd/25d3de34-4e88-4de5-b53f-c7d9ddeda6d4